MedTrace Logo

Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

NCT04298515 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-03-06

No results posted yet for this study

Summary

This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Conditions

Interventions

DIAGNOSTIC_TEST

Nesfatin-1

Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Sponsors & Collaborators

  • Istanbul Medeniyet University

    lead OTHER

Principal Investigators

  • Gülin Öztürk Özkan, Assis Prof · İstanbul Medeniyet University

  • Kadir Kayataş, associate professor · Haydarpaşa Numune Education and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-02
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298515 on ClinicalTrials.gov